Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1/2 Trial Integrating Allogeneic NK Cells in High-risk Advanced Stage III-IV Nasopharyngeal Cancer Patients

NCT07247201 is registered in ClinicalTrials.gov with Singapore General Hospital as lead sponsor.

NCT NCT07247201
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07247201 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1/2 Trial Integrating Allogeneic NK Cells in High-risk Advanced Stage III-IV Nasopharyngeal Cancer Patients
Lead sponsor
Singapore General Hospital
Phase
Phase 1/2
Overall status
Not yet recruiting
Start date
April 30, 2026
Completion date
September 30, 2026
Enrollment
31 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

maximum tolerated dose, minimal residual disease, nasopharyngeal carcinoma (npc), recurrent nasopharyngeal carcinoma